Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smaller stent tame brain fog after liver shunt surgery?

NCT ID NCT07799948

Disease control Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study tests a refined procedure for people who develop severe, recurring hepatic encephalopathy after a TIPS procedure, a shunt placed to relieve pressure in the liver. The technique uses a coil and a smaller covered stent to narrow the shunt and reduce blood flow, aiming to ease symptoms while keeping the shunt working. Researchers will follow 30 patients, both past and new, to see if the procedure lowers the frequency of encephalopathy episodes and whether it causes complications like stent blockage or bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A procedure that places a coil and a smaller covered stent inside the existing TIPS shunt to narrow it and reduce blood flow.
What this could lead to
If it works, this technique could offer a safer, more precise way to ease severe hepatic encephalopathy in people who still have symptoms despite standard treatment.
What could go wrong
This is a small, single-center study, so results may not apply broadly. The procedure carries risks like stent blockage, bleeding, or worsening of other portal hypertension complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Prior transjugular intrahepatic portosystemic shunt (TIPS) placement; 2. Confirmation of patent TIPS stent via imaging and/or hemodynamic evaluation; 3. Recurrent episodes of grade II or higher hepatic encephalopathy (by West-Haven criteria) occurring more than twice within a 4-week period, despite standard medical therapy including lactulose, rifaximin, nutritional support, and correction of precipitating factors; 4. Treatment with coil-assisted small-diameter stent shunt reduction; 5. Signed informed consent provided by the patient or legal representative (for the prospective cohort). Exclusion Criteria 1. Presence of severe extrahepatic organ failure (e.g., cardiac, pulmonary, or renal failure); 2. Significant missing data that precludes evaluation in the retrospective cohort.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic encephalopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatic encephalopathy portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic encephalopathy Liver cirrhosis Portal hypertension Transjugular intrahepatic portosystemic shunt (TIPS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Air Force Military Medical University

    RECRUITING

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.